J 2021

Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report

SIN, Robin a Denisa ŠTRUNCOVÁ

Základní údaje

Originální název

Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report

Autoři

SIN, Robin (203 Česká republika) a Denisa ŠTRUNCOVÁ (203 Česká republika, garant, domácí)

Vydání

World Journal of Clinical Cases, PLEASANTON, BAISHIDENG PUBLISHING GROUP INC, 2021, 2307-8960

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 1.534

Kód RIV

RIV/00216224:14110/21:00124181

Organizační jednotka

Lékařská fakulta

UT WoS

000727979500031

Klíčová slova anglicky

SARS-CoV-2; COVID-19; mRNA vaccine; Complication of vaccination; Status epilepticus; Case report

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 3. 3. 2022 13:21, Mgr. Tereza Miškechová

Anotace

V originále

BACKGROUND We present a rare case of status epilepticus in a 56-year-old man which arose as a complication after vaccination with the coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine. The patient's history included well-compensated secondary epilepsy. The root cause of the situation was a fever which had developed as a side effect of the vaccination. CASE SUMMARY A 56-year-old man received the first dose of mRNA-1273 vaccine against the severe acute respiratory syndrome-coronavirus-2. The vaccine was administered intramuscularly (100 mg, 0.5 mL). The next morning the man was found to be suffering from fever and headaches while at the same time experiencing general weakness. He lost consciousness suddenly and experienced generalized clonic seizures which turned into status epilepticus. When the Emergency Medical Service arrived the patient was unconscious with spontaneous breathing and generalized clonic seizures. It was necessary to administer diazepam repeatedly. It was also necessary to administer high doses of levetiracetam and temporary propofol. The status epilepticus was brought under control approximately 90 min after the patient's transport to the Emergency Department. A follow-up electroencephalogram no longer revealed abnormal indications of epileptic fit. The patient was temporarily hospitalized in the Intensive Care Unit and after seven days care was discharged without any further apparent effects. CONCLUSION There is currently no specific treatment against COVID-19. Therefore, the benefits of COVID-19 vaccine protection outweigh the risks.